ReviewParasitology research2008
Leishmaniasis treatment--a challenge that remains: a review.
Review in Parasitology research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed.
- Isoxazole Derivative Induces Apoptosis-like Death and Autophagy through Oxidative Stress inACS omega · 2026Article
- Identification of Bioactive Metabolites ofMetabolites · 2025Article
- Evaluation of the Anti-Leishmanial Activity of the Hydroalcoholic Extract of Green Algae (Spirogyra): Investigation of Weight Indicators (Lesion Size and Organ Weights) in BALB/c Mice.Acta parasitologica · 2025Article
- A novel inhibitory strategy ofFuture microbiology · 2025Article
- Synthesis and evaluation of nitrochromene derivatives as potential antileishmanial therapeutics through biological and computational studies.Scientific reports · 2025Article
- Antileishmanial potential of thiourea-based derivatives: design, synthesis and biological activity.RSC advances · 2024Article
- Environmental impacts of drugs against parasitic vector-borne diseases and the need to integrate sustainability into their development and use.Open research Europe · 2024Article
- Triethyl phosphine decorated cerium oxide nanoparticles exhibit selective killing of the unicellular protozoan parasite3 Biotech · 2023Article
- In vitro and in vivo antileishmanial effects ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- A Novel Topical Formulation of the Leishmaniasis Drug Glucantime as a Nanostructured Lipid Carrier-Based Hydrogel.The American journal of tropical medicine and hygiene · 2023Article
- Leishmanicidal and immunomodulatory activities of the formononetin (a natural isoflavone) against Leishmania tropica.BMC research notes · 2023Article
- Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?Microorganisms · 2023Article
- Antileishmanial Activity of the Essential Oils from Three Trees Obtained in Different Phenological Stages.Acta parasitologica · 2023Article
- Low doses of 3-phenyl-lawsone or meglumine antimoniate delivery by tattooing route are successful in reducing parasite load in cutaneous lesions ofFrontiers in cellular and infection microbiology · 2023Article
- Elucidating the role played by bone marrow in visceral leishmaniasis.Frontiers in cellular and infection microbiology · 2023Review
- A Review: Meridianins and Meridianins Derivatives.Molecules (Basel, Switzerland) · 2022Review
- Novel 3-chloro-6-nitro-1Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Antileishmanial Activities of Medicinal Herbs and Phytochemicals In Vitro and In Vivo: An Update for the Years 2015 to 2021.Molecules (Basel, Switzerland) · 2022Review
- Chemical composition, antileishmanial, and cytotoxic effectsParasite epidemiology and control · 2022Article
- Unravelling the antifungal and antiprotozoal activities and LC-MS/MS quantification of steroidal saponins isolated fromRSC advances · 2022Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is a disease caused by flagellate protozoan Leishmania spp. and represents an emergent illness with high morbidity and mortality in the tropics and subtropics. Since the discovery of the first drugs for Leishmaniasis treatment (i.e., pentavalent antimonials), until the current days, the search for substances with antileishmanial activity, without toxic effects, and able to overcome the emergence of drug resistant strains still remains as the current goal. This article reports the development of new chemotherapies through the rational design of new drugs, the use of products derived from microorganisms and plants, and treatments related to immunity as new alternatives for the chemotherapy of leishmaniasis.
Indexed as
Identifiers
18389282What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.